QUALITY OF RAC SCIENTIFIC REVIEW OF GENE THERAPY PROTOCOLS QUESTIONED BY NIH DIRECTOR VARMUS AT AD HOC PANEL; HE SUGGESTS CENTERS FOR EXCELLENCE
The scientific review process of gene therapy protocols as conducted by the National Institutes of Health Recombinant DNA Advisory Committee is in need of close evaluation, NIH Director Harold Varmus, MD, said at the first meeting of the ad hoc review committee of the RAC Feb. 3.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth